This commentary explores recent advances in longterm prophylaxis for hereditary angioedema HAE focusing on new clinical trial data for garadacimab and donidalorsen and the impact of social determinants on HAE management Key findings presented at the 2024 American College of Allergy Asthma and Immunology meeting highlight the potential of these therapies to improve quality of life while underscoring the need for equitable access to preventive care across diverse patient populations
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/allergy-and-immunology/ltp-for-hae-emerging-insights/30557-59806
- Start Date: 2024-11-04 06:00:00
- End Date: 2024-11-04 06:00:00
- Credit Details: IPCE Credits: 0.25 hours
AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours - Commercial Support: Source: Ionis Pharmaceuticals Inc - Amount: 18750.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest